Rapid Medical’s Comaneci Embolization-Assist Device Compared With Stent- and Balloon-Assisted Coiling Devices

July 19, 2023—Rapid Medical, an Israel-based developer of neurovascular devices, announced new clinical data showing significant advantages of the company’s Comaneci embolization-assist device versus established techniques of stent-assisted coiling (SAC) and balloon-assisted coiling (BAC) techniques to treat ruptured wide-neck intracranial aneurysms.

Rapid Medical’s Comaneci is an adjustable, nonocclusive device for hemorrhagic stroke treatment. The device’s visible mesh conforms to the anatomy, providing stent-like support without the complications of a permanent stent or halting blood flow like a balloon. It has been used worldwide to treat wide-neck aneurysms and in Europe only, to open arteries constricted by vasospasm, advised the company.

Data from a recent meta-analysis conducted at the University at Buffalo in Buffalo, New York, and George Washington University in Washington, DC, were published by Jaims Lim, MD, et al in World Neurosurgery (2023;175:e1324-e1340).

According to the company, the investigators found that Comaneci is associated with lower hemorrhagic and thromboembolic complication rates, higher complete occlusion rates, and similar residual retreatment rates than SAC and BAC techniques.

“The Comaneci device is a highly useful adjunct tool for patients with subarachnoid hemorrhage,” commented study investigator Adnan Siddiqui, MD, in Rapid Medical’s press release. “While SAC and BAC are widely used therapies, each method has unique drawbacks that are nicely addressed with the Comaneci device.” Dr. Siddiqui is Vice-Chairman and Professor of Neurosurgery at University at Buffalo and CEO of the Jacobs Institute in Buffalo, New York.

In the study, investigators compared the three devices by pooling > 3,200 ruptured aneurysms across 64 studies. No significant differences were found between SAC and BAC. However, Comaneci-assisted coiling showed significantly lower thromboembolic and aneurysmal complication rates and periprocedural complications than both SAC and BAC. Furthermore, Comaneci demonstrated statistically better complete occlusion rates than SAC and equivalent rates to BAC, reported Rapid Medical.